Du är nu på väg att lämna en GSK-hemsida

Denna länk leder till en hemsida som inte tillhör GSK. GSK tar inget ansvar för innehållet på tredje parts hemsidor.



Nucala in 4 eosinophilic diseases

Nucala is the anti-IL-5 therapy that is approved for the treatment of 4 eosinophilic diseases.1

Since March 2016 Nucala has been approved as an add-on treatment for SEA (severe eosinophilic asthma) in adults, adolescents and children aged 6 years and older. At the end of 2021 (November 2021) Nucala has also been approved for 3 other eosinophilic diseases in Norway: CRSwNP (chronic rhinosinusitis with nasal polyps), EGPA (eosinophilic granulomatosis with polyangiitis) and HES (hypereosinophilic syndrome).1

For relevant scientific information on each indication, click on the button.


Nucala is a trademark of the GSK group of companies

PM-NO-MPL-WCNT-230001 June 2023